1. Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
- Author
-
David Campbell, James Schmeits, Shu-Hui Chen, Denise Hanway, David T. Winn, Wensheng Liao, Ruzhang Liu, Juan M. Betancort, Junjuan Liu, David P. Carney, Quansheng Xu, Xinqiang Li, and Eric M. Gordon
- Subjects
Pyrrolidines ,Time Factors ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Biochemistry ,Chemical synthesis ,Catalysis ,Inhibitory Concentration 50 ,Structure-Activity Relationship ,chemistry.chemical_compound ,Nitriles ,Drug Discovery ,Diabetes Mellitus ,Humans ,Enzyme Inhibitors ,Molecular Biology ,Dipeptidyl peptidase-4 ,chemistry.chemical_classification ,Dipeptidyl-Peptidase IV Inhibitors ,Molecular Structure ,Bicyclic molecule ,biology ,Organic Chemistry ,In vitro ,Protein Structure, Tertiary ,Thiazoles ,Enzyme ,Models, Chemical ,chemistry ,Enzyme inhibitor ,Drug Design ,Lactam ,biology.protein ,Thiazolidines ,Molecular Medicine ,Selectivity ,Azabicyclo Compounds - Abstract
The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species. The inhibitors show good to moderate biochemical potency against DPP4 and display distinct selectivity profiles towards DPP7, DPP8 and DPP9 depending on their substitution.
- Published
- 2009
- Full Text
- View/download PDF